Hero Image

5 New Parkinson's Disease Breakthroughs

If you're ready to act on new Parkinson's disease breakthroughs, this guide shows what's real, who it may fit, and how to access options sooner.

Whether you're newly diagnosed or several years into treatment, you'll find clear next steps to discuss with your movement disorder specialist.

Are breakthrough treatments right for you?

Breakthroughs aren't one-size-fits-all. Some options target specific genetics (like LRRK2 variants), others are symptom-focused (tremor control), and a few aim to slow progression. Your best first move is a consult with a movement disorder specialist—neurologists with advanced PD expertise—ideally at a Parkinson's Foundation Center of Excellence. Bring your medication list, response patterns (on/off times), and goals (e.g., fewer fluctuations, less tremor, slower decline).

Most “new” options are available through clinical trials or specialized centers; some are FDA-approved for specific symptoms but not disease modification. Align your choice with your stage of disease, tolerance for risk, and willingness to travel for care. Be cautious of pay-to-participate clinics claiming cures without peer-reviewed data.

5 new Parkinson's disease breakthroughs to consider now

1) GLP-1 receptor agonists (lixisenatide, exenatide): metabolic reprogramming

GLP-1 drugs—originally diabetes medications—are being repurposed in PD because they may counter inflammation, mitochondrial dysfunction, and insulin resistance in the brain. A randomized trial reported that a GLP-1 agent slowed motor decline over 12 months in early PD, fueling a wave of studies across the class. Results with exenatide have been mixed, but the overall signal remains promising.

How to access:

  • Clinical trials first: Search open studies of GLP-1 drugs in PD on ClinicalTrials.gov. Many accept non-diabetic participants.
  • Off-label discussion: Some people explore GLP-1 agents off-label with their specialist when trials aren’t an option. Discuss potential GI side effects, weight loss, pancreatitis risk, and cost/coverage.
  • Learn the landscape: The Michael J. Fox Foundation’s overview is a solid primer: GLP-1 drugs and Parkinson’s.

Who it may fit: Early to mid-stage PD, motivated to try a systemic therapy with weekly or daily dosing; comfortable with injections (for most agents) and regular monitoring.

2) LRRK2 inhibitors: targeted, potentially disease-modifying therapy

Mutations in LRRK2 are one of the most common genetic causes of PD. Small-molecule inhibitors of LRRK2 (e.g., BIIB122/DNL151) are in late-stage trials for both LRRK2-associated and idiopathic PD. These drugs aim to normalize overactive kinase signaling implicated in neuronal stress.

How to access:

  • Know your genetics: Free testing and counseling are available via PD GENEration. Knowing if you carry LRRK2 (or GBA1) can open trial doors.
  • Find active trials: Example listing for an early PD study of BIIB122: NCT05348785. You can also follow the science via MJFF’s LRRK2 research hub.

Who it may fit: Early PD (with or without known LRRK2 variants), willing to join a placebo-controlled study and complete biomarker visits (blood/urine/lung function monitoring for safety).

3) Stem cell–derived dopamine neuron replacement (bemdaneprocel/DA01)

Cell therapy aims to replace lost dopamine neurons, potentially restoring circuit function. An investigational product (bemdaneprocel/DA01) derived from pluripotent stem cells showed encouraging safety and feasibility signals in an early-phase study, with imaging and clinical trends supporting further research.

How to access:

  • Clinical trial sites: See the ongoing study page: NCT04852721, and company updates from BlueRock Therapeutics here. Eligibility is strict (age, disease stage, medication stability, MRI/PET imaging).
  • Avoid unregulated clinics: In the U.S., most stem cell interventions for PD remain investigational. Review the FDA’s consumer alert on unapproved “stem cell” offerings: FDA guidance.

Who it may fit: Mid-stage PD with motor complications despite best medical therapy; willing to undergo neurosurgery and intensive follow-up in a research setting.

4) Incisionless focused ultrasound (MRgFUS) for tremor-dominant PD

MR-guided focused ultrasound is a noninvasive procedure that uses targeted acoustic energy to create a precise lesion in deep brain structures involved in tremor. It’s FDA-approved in the U.S. for medication-refractory essential tremor and unilateral tremor-dominant PD, offering immediate tremor relief for the treated side without incisions.

How to access:

  • Find a center: Start with patient resources from the Focused Ultrasound Foundation: PD and focused ultrasound, or review therapy details from device makers like Insightec: Exablate Neuro.
  • Insurance and expectations: Coverage varies by payer and state; many centers can pre-authorize. Note it is typically unilateral and symptom-focused (not disease-modifying).

Who it may fit: People with disabling unilateral tremor who are poor candidates for DBS or prefer a non-implant option.

5) Adaptive deep brain stimulation (aDBS) and sensing neurostimulators

Next-generation DBS systems can sense brain activity and adjust stimulation in real time, aiming for fewer side effects and better battery life. While true closed-loop algorithms are mostly in trials, sensing-capable devices are commercially available and can support research updates via software.

How to access:

  • Talk to a DBS center: Ask about sensing-enabled systems (e.g., Medtronic Percept) and whether you might qualify for adaptive DBS studies. Device overview: Percept PC.
  • Explore trials: See ongoing aDBS research: adaptive DBS trials.

Who it may fit: Candidates for standard DBS who want cutting-edge programming options, or existing DBS users considering a future upgrade.

Your 14-day action plan

  • Day 1–2: Book the right visit with a movement disorder specialist (ideally at a Center of Excellence). Share your priority (e.g., slow progression vs. control tremor).
  • Day 3–5: Get your records in order: medication timeline, motor diary (on/off, dyskinesias), prior imaging, and a list of past side effects.
  • Day 6–7: Consider genetic testing via PD GENEration to learn if targeted trials (e.g., LRRK2, GBA1) fit you.
  • Day 8–10: Pre-screen trials with Fox Trial Finder and ClinicalTrials.gov. Check logistics (location, visit frequency) and inclusion/exclusion criteria.
  • Day 11–12: Insurance and costs: Contact your payer about MRgFUS or DBS coverage; ask clinics about financial counselors. For meds, explore assistance like the PAN Foundation.
  • Day 13–14: Decide with your clinician: Weigh benefits, risks, and alternatives. Confirm a monitoring plan (A1c/weight for GLP-1, lung function/renal markers for LRRK2 trials, imaging for cell therapy).

Costs, access, and safety—quick answers

  • Trials are often no-cost for study drugs and research tests; travel support may be available. Ask coordinators directly.
  • Off-label medications may involve prior authorization; document medical need and intolerance of alternatives.
  • Surgical innovations (MRgFUS/DBS) typically require center-based evaluation; request a written summary of risks, alternatives, and expected outcomes.
  • Expanded access can be an option when trials aren’t feasible; learn the process via the FDA’s Expanded Access page.
  • Clinical trial basics: If you’re new to research, review the NIH’s guide: Participating in clinical trials.

Bottom line

There’s real momentum in Parkinson’s treatment—repurposed metabolic drugs, precision gene-targeted therapies, restorative cell approaches, and smarter device-based care. None are magic bullets, but with the right specialist and a clear plan, you can pursue a breakthrough pathway that matches your goals and risk tolerance. This article is informational and not medical advice; partner with your care team to choose the safest, most effective next step for you.